- US-listed companies
- Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc.XERS
Market cap
$400.56M
P/E ratio
Dec 31, 2021 | Dec 31, 2022 | Jun 30, 2023 | |
Product | - | 109 | 69 |
Royalty, contract and other revenue | - | 1 | 2 |
Net sales | 50 | 110 | 71 |
Cost of goods sold | 13 | 23 | 13 |
Research and development | 25 | 21 | 11 |
Selling, general and administrative | 126 | 138 | 71 |
Amortization of Intangible Assets | 1 | 11 | 5 |
Total operating expenses | 165 | 192 | 100 |
Loss from operations | -115 | -82 | -29 |
Interest Income, Other | 0 | 3 | 3 |
Interest expense | 7 | 15 | 13 |
Change in fair value of warrants | 1 | -2 | 0 |
Change in fair value of contingent value rights | - | 3 | -2 |
Other income (expense) | -8 | -14 | -8 |
Net loss before benefit from income taxes | -123 | -96 | -37 |
Benefit from income taxes | - | -1 | -1 |
Net loss | -123 | -95 | -37 |
Unrealized gains (losses) on investments | -0 | 0 | -0 |
Foreign currency translation adjustments | 0 | 0 | - |
Comprehensive loss | -123 | -95 | -37 |
Earnings Per Share, Basic | - | -0.7 | -0.27 |
Earnings Per Share, Diluted | - | -0.7 | -0.27 |